ArticlePDF Available

A Scientific review on clot dissolving activity of cayenne pepper

Authors:

Abstract

The work of fibrinolysis is to break up fibrin clots. The a glycoprotein with gram atomic weight (GMW) of 90,000. plasminogen is changed over to plasmin by tissue plasminogen activator (TPA). happens on the fibrin surface, in this way restricting proteolytic location. Tissue plasminogen activator, produced by monoclonal methods, has recently been made available for limited therapeutic use. As of now are broadly utilized remedially to enact plasminogen. These shaped which is free in the circulation as well as bound to fibrin, proteolysis of circulating plasminogen and clotting components has demonstrated to be more useful than anticoagulation alone for and for aspiratory emboli. Herbs and species are natural foods additives that contribute significantly to the taste and flavor of our food. In some cult spices have also been used as medicines. Cayenne pepper is one among them which belongs to the family solanaceae. It is a type of Capsicum annum. It is usually a hot chili powder that is used to flavor dishes. Th present in most of the Capsicum species is capsaicin dissolving potential. This present review focuses on providing the information about the Capsaicin. It is usually a dishes. The word kynnha which from the city of is high in product2. The it is Capsaicin property17. an anticoagulant K-dependent than that of Taxonomical classification: 17  Kingdom: Plantae  Order: Solanales  Family: Solanaceae  Genus: Capsicum  Species: annuum Fig No 1 Cayenne pepper Therapeutic uses of Cayenne pepper:  Boosts metabolism  Improves Digestive Health  Lowers Blood Pressure  Can reduce pain  Anti-Cancer  Protects the Heart8 Impact Factor: SJIF: 5.995 ; 10572-10574 //2018.10574.1796 and Kavya K operator of fibrinolysis is plasmin, Beneath normal conditions, Actuation movement to the suitable . Streptokinase and Urokinase specialists cause plasmin to be coming about in components. Fibrinolytic treatment profound vein thrombi cultures, these herbs and r The main chemical constituent (48.6%) which has clot 20
A SCIENTIFIC REVIEW ON CLOT
Sai Sri lakshmi G*.,
Naga varalakshmi T., Sai kiran A., Vindhya G., Sundar Raj I
Sai kiran, D.no:1
A R T I C L E I N F O
INTRODUCTION
Cayenne pepper is a type of Capsicum
annum.
moderate hot chili pepper used to flavor
cayenne is derived from the old tupi
language
means pepper. Cayenne pepper gets its
name
Cayenne in French Guiana.21 Cayenne
pepper
vitamin A. It also contains vitamin B,
vitamin E, vitamin C,
riboflavin, potassium and manganese.16,17,18
Plan Profile
Cayenne pepper is a naturally occurring
plant
main active chemical constituent present
in
which has an anti-coagulant and anti-
inflammatory
While coming to the synthetic Warfarin, it
is
that acts by inhibiting the synthesis
of vitamin K
coagulation factors. Warfarin has more side
effects
Cayenne pepper.18
Synonyms: 16,18
Capsicum annuum
Capsicum angulosum
Capsicum frutescens
Capsicum minimum
International Journal of Current Advanced Research
ISSN: O: 2319-6475, ISSN: P: 2319-
6505,
Available Online at
www.journalijcar.org
Volume 7; Issue 3(B); March 2018
; Page No.
DOI: http:
//dx.doi.org/10.24327/ijcar.2018
Copyright©2018 Sai Sri lakshmi G et al.
This is an open access article distributed under the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
*Corresponding author: Sai Sri lakshmi G
Sai kiran, D.no:1-
355,1st Ward, Katapheta, Mangalagiri
Article History:
Received 6th December, 2017
Received in revised form 21st
January, 2018 Accepted 05th February, 2018
Published online 28th March, 2018
Key words:
Cayenne pepper, Capsaicin, Clot dissolving
activity
A SCIENTIFIC REVIEW ON CLOT DISSOLVING ACTIVITY OF CAYENNE PEPPER
Naga varalakshmi T., Sai kiran A., Vindhya G., Sundar Raj I
Sai kiran, D.no:1
-
355,1st Ward, Katapheta, Mangalagiri
A B S T R A C T
The work of fibrinolysis is to break up
fibrin clots. The
a glycoprotein with gram atomic
weight (GMW) of 90,000.
plasminogen is changed over
to plasmin by tissue plasminogen activator (TPA).
happens on the fibrin surface, in this way restricting
proteolytic
location
. Tissue plasminogen activator, produced by monoclonal methods, has recently
been made available for limited therapeutic use.
As of now
are broadly utilized remedially to enact
plasminogen. These
shaped
which is free in the circulation as well as bound to fibrin,
proteolysis of circulating plasminogen and clotting
components
has demonstrated to be more useful
than anticoagulation alone for
and for aspiratory
emboli. Herbs and species are natural foods additives that contribute
significantly to the taste and flavor of our food. In some cult
spices have also been used as medicines. Cayenne pepper is one among them
which belongs to the family solanaceae. It is a type of Capsicum annum. It is usually
a hot chili powder that is used to flavo
r dishes. Th
present in most of the Capsicum species is
capsaicin
dissolving potential. This present review focuses on providing the information about the
Capsaicin.
annum.
It is usually a
dishes. The word
language
kynnha which
name
from the city of
pepper
is high in
vitamin E, vitamin C,
plant
product2. The
in
it is Capsaicin
inflammatory
property17.
is
an anticoagulant
of vitamin K
-dependent
effects
than that of
Taxonomical classification: 17
Kingdom: Plantae
Order: Solanales
Family: Solanaceae
Genus: Capsicum
Species: annuum
Fig No 1
Cayenne pepper
Therapeutic uses of Cayenne pepper:
Boosts metabolism
Improves Digestive Health
Lowers Blood Pressure
Can reduce pain
Anti-Cancer
Protects the Heart8
International Journal of Current Advanced Research
6505,
Impact Factor: SJIF: 5.995
www.journalijcar.org
; Page No.
10572-10574
//dx.doi.org/10.24327/ijcar.2018
.10574.1796
This is an open access article distributed under the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
355,1st Ward, Katapheta, Mangalagiri
DISSOLVING ACTIVITY OF CAYENNE PEPPER
Naga varalakshmi T., Sai kiran A., Vindhya G., Sundar Raj I
and Kavya K
355,1st Ward, Katapheta, Mangalagiri
fibrin clots. The
operator of fibrinolysis is plasmin,
weight (GMW) of 90,000.
Beneath normal conditions,
to plasmin by tissue plasminogen activator (TPA).
Actuation
proteolytic
movement to the suitable
. Tissue plasminogen activator, produced by monoclonal methods, has recently
As of now
Streptokinase and Urokinase
plasminogen. These
specialists cause plasmin to be
which is free in the circulation as well as bound to fibrin,
coming about in
components
. Fibrinolytic treatment
than anticoagulation alone for
profound vein thrombi
emboli. Herbs and species are natural foods additives that contribute
significantly to the taste and flavor of our food. In some cult
ures, these herbs and
spices have also been used as medicines. Cayenne pepper is one among them
which belongs to the family solanaceae. It is a type of Capsicum annum. It is usually
r dishes. Th
e main chemical constituent
capsaicin
(48.6%) which has clot
dissolving potential. This present review focuses on providing the information about the
Cayenne pepper
Therapeutic uses of Cayenne pepper:
20
Improves Digestive Health
Lowers Blood Pressure
Review Article
International Journal of Current Advanced Research Vol 7, Issue 3(B), pp 10572-10574, March 2018
10573
Clears congestion
Weight loss
Helps Detoxify
Relieves Joint Pains
Has Anti-microbial properties
Improves immunity6
Can Heal Toothaches
Improves Skin And Hair Health
Folklore uses: Stimulant, tonic, carminative, pungent, emetic,
antiseptic, antispasmodic, rubefacient, condiment and anti-
rheumatic.19
Mechanism of Cayenne pepper in dissolving the blood clot
They are potent blood anticoagulants from the east, used as a
cooking necessity.1 They prevent the platelets from sticking
together thereby easing the blood flow.3 Cayenne peeper
contains a compound called Capsaicin which ensures proper
blood flow throughout the vessels. It also helps
reduce symptoms of poor blood circulation like pain,
headaches,10 numb hands, cold feet and tingling in legs.9
Fig No 2 Mechanism of Fibrinolysis11,12
Human Polymorphisms Associated With Thrombosis
Table 1 Some examples of human polymorphisms associated
with thrombosis.14,15
Polymorphism Hemostatic phenotype
PAI-1 4G promoter Increased venous thrombosis risk, slightly
increased arterial thrombosis risk, no apparent
increase in stroke risk24
tPA enhancer 7531 C/T Increased arterial thrombosis in select
populations25
TAFI Thr325Ile Increased circulating TAFI, but no increase in
thrombosis15
TAFI Ala147Thr Increased risk for coronary artery disease
14
Disorders of fibrinolysis can be congenital or acquired in
association with numerous medical conditions including
malignancy, liver disease12, and renal failure18.
Hypofibrinolysis is more often associated with thrombosis11,
while hyperfibrinolysis may result in a bleeding
tendency17.Defects in fibrinolytic components have been
associated with non-hematologic manifestations such as
ligneous mucositis. Global assays of fibrinolysis developed to
predict thrombosis should be validated in larger populations,
and further studied for use in bleeding disorder.16
Major drug interaction:1
CONCLUSION
Capsaicin, the dynamic rule of hot peppers of the class
Capsicum, displays expansive bioactivity. It targets neuronal
structures which contain substance P, clinically observed as
gastrointestinal and dermatologic disturbance, bronchospasm
and fibrinolysis. Capsaicin is an agonist of transient receptor
potential vanilloid compose 1 (TRPV1), in which it can go
about as a neuronal stimulant and result in nociception.
Capsaicin likewise influences an assortment of nonneuronal
tissues, in which its instruments of activity are less sure. The
fibrinolytic framework is as convoluted and multifaceted as the
coagulation course, and is similarly significant thrombotic
sickness and dying. Dysregulation of the fibrinolytic
framework is related with various and capricious clinical
phenotypes going from the coagulopathies of liver sickness12
and DIC to uncommon inborn draining issue. Likewise, the
potential part of the fibrinolytic framework in cell flagging
pathways, irritation, and harm stays to be completely
investigated. The fibrinolytic framework speaks to a genuine
boondocks in understanding the intricate communications of
natural frameworks, and, as we pick up a superior
comprehension of its part in science, we will have the capacity
to enhance the care of patients with assorted medicinal
conditions.
References
1. Broos K, Feys HB, De Meyer SF, Vanhoorelbeke K,
Deckmyn H. Platelets at work in primary
hemostasis. Blood Rev. 2011; 25(4):155 -67. [PubMed]
2. De Witt SM, Verdoold R, Cosemans JM, Heemskerk
JW. Insights into platelet-based control of
coagulation. Thromb Res. 2014; 133(Suppl 2):S139 -
48. [PubMed]
3. Furie B. Pathogenesis of thrombosis. Hematology Am
Soc Hematol Educ Program. 2009:255 -8.[PubMed]
4. Bagoly Z, Koncz Z, Hársfalvi J, Muszbek L. Factor
XIII, clot structure, thrombosis. Thromb Res. 2012;
129(3):382 -7. [PubMed]
5. Hajjar KA. The molecular basis of fibrinolysis. In:
Orkin SA, Nathan DG, Ginsburg D, Look AT, Fisher
DE, Lux SE, editors. Nathan and Orkin’s Hematology
of Infancy and Childhood. 8. Philadelphia:
Saunders/Elsevier; 2014.
6. Wolberg AS. Thrombin generation and fibrin clot
structure. Blood Rev. 2007;21(3):131 -42. [PubMed]
7. Crowther MA, Roberts J, Roberts R, Johnston M,
Stevens P, Skingley P, et al. Fibrinolytic variables in
patients with recurrent venous thrombosis: a prospective
cohort study. Thromb Haemost. 2001;85(3):390 -
4. [PubMed]
8. Folsom AR, Cushman M, Heckbert SR, Rosamond
WD, Aleksic N. Prospective study of fibrinolytic
markers and venous thromboembolism. J Clin
Epidemiol. 2003; 56(6):598 -603. [PubMed]
9. Lisman T, de Groot PG, Meijers JC, Rosendaal FR.
Reduced plasma fibrinolytic potential is a risk factor for
A Scientific Review on Clot Dissolving Activity of Cayenne Pepper
10574
venous thrombosis. Blood. 2005;105(3):1102 -
5. [PubMed]
10. Hoekstra J, Guimarães AH, Leebeek FW, Darwish
Murad S, Malfliet JJ, Plessier A, et al. Impaired
fibrinolysis as a risk factor for Budd -Chiari
syndrome. Blood. 2010;115(2):388 -95. [PubMed]
11. De Wee EM, Klaij K, Eikenboom HC, Van Der Bom
JG, Fijnvandraat K, Laros-Van Gorkom BA, et al.
Effect of fibrinolysis on bleeding phenotype in
moderate and severe von Willebrand
disease. Haemophilia. 2012;18(3):444 -51. [PubMed]
12. Rijken DC, Kock EL, Guimarães AH, Talens S,
Darwish Murad S, Janssen HL, et al. Evidence for an
enhanced fibrinolytic capacity in cirrhosis as measured
with two different global fibrinolysis tests. J Thromb
Haemost. 2012;10(10):2116 -22. [PubMed]
13. Sivula M, Pettilä V, Niemi TT, Varpula M, Kuitunen
AH. Thromboelastometry in patients with severe sepsis
and disseminated intravascular coagulation. Blood
Coagul Fibrinolysis. 2009;20(6):419 -26.[PubMed]
14. Ogawa S, Szlam F, Chen EP, Nishimura T, Kim H,
Roback JD, et al. A comparative evaluation of rotation
thromboelastometry and standard coagulation tests in
hemodilution-induced coagulation changes after cardiac
surgery. Transfusion. 2012;52(1):14 -22. [PubMed]
15. Brazzel C. Thromboelastography-guided transfusion.
Therapy in the trauma patient. AANA J. 2013;81(2):127
-32. [PubMed]
16. https://en.wikipedia.org/wiki/Cayenne_pepper#Etymolo
gy
17. http://www.stylecraze.com/articles/top-10-health-
benefits-of-cayenne pepper/#WhatIsCayennePepper?
file:///E:/cayenne.pdf
18. http://www.herbalpedia.com/cayenne.pdf
19. Nikolopoulos GK, Bagos PG, Tsangaris I, Tsiara CG,
Kopterides P, Vaiopoulos A, et al. The association
between plasminogen activator inhibitor type 1 (PAI-1)
levels, PAI-1 4G/5G polymorphism, and myocardial
infarction: a Mendelian randomization meta-
analysis. Clin Chem Lab Med. 2014;52(7):937 -
50. [PubMed]
20. Jannes J, Hamilton-Bruce MA, Pilotto L, Smith BJ,
Mullighan CG, Bardy PG, et al. Tissue plasminogen
activator −7351C/T enhancer polymorphism is a risk
factor for lacunar stroke. Stroke. 2004;35(5):1090 -
4. [PubMed]
How to cite this article:
Sai Sri lakshmi G et al (2018) 'A Scientific Review on Clot Dissolving Activity of Cayenne Pepper', International Journal of
Current Advanced Research, 07(3), pp. 10572-10574. DOI: http://dx.doi.org/10.24327/ijcar.2018.10574.1796
*******
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
Background: The circulating levels of plasminogen activator inhibitor type 1 (PAI-1) are increased in individuals carrying the 4G allele at position -675 of the PAI-1 gene. In turn, overexpression of PAI-1 has been found to affect both atheroma and thrombosis. However, the association between PAI-1 levels and the incidence of myocardial infarction (MI) is complicated by the potentially confounding effects of well-known cardiovascular risk factors. The current study tried to investigate in parallel the association of PAI-1 activity with the PAI-1 4G/5G polymorphism, with MI, and some components of metabolic syndrome (MetS). Methods: Using meta-analytical Mendelian randomization approaches, genotype-disease and genotype-phenotype associations were modeled simultaneously. Results: According to an additive model of inheritance and the Mendelian randomization approach, the MI-related odd ratio for individuals carrying the 4G allele was 1.088 with 95% confidence interval (CI) 1.007, 1.175. Moreover, the 4G carriers had, on average, higher PAI-1 activity than 5G carriers by 1.136 units (95% CI 0.738, 1.533). The meta-regression analyses showed that the levels of triglycerides (p=0.005), cholesterol (p=0.037) and PAI-1 (p=0.021) in controls were associated with the MI risk conferred by the 4G carriers. Conclusions: The Mendelian randomization meta-analysis confirmed previous knowledge that the PAI-1 4G allele slightly increases the risk for MI. In addition, it supports the notion that PAI-1 activity and established cardiovascular determinants, such as cholesterol and triglyceride levels, could lie in the etiological pathway from PAI-1 4G allele to the occurrence of MI. Further research is warranted to elucidate these interactions.
Article
Full-text available
In Budd-Chiari syndrome (BCS), thrombosis develops in the hepatic veins or inferior vena cava. To study the relationship between hypofibrinolysis and BCS, we measured plasma levels of fibrinolysis proteins in 101 BCS patients and 101 healthy controls and performed a plasma-based clot lysis assay. In BCS patients, plasminogen activator inhibitor 1 (PAI-1) levels were significantly higher than in controls (median, 6.3 vs 1.4 IU/mL, P < .001). Thrombin-activatable fibrinolysis inhibitor and plasmin inhibitor levels were lower than in controls (13.8 vs 16.9 microg/mL and 0.91 vs 1.02 U/L, both P < .001). Median plasma clot lysis time (CLT) was 73.9 minutes in cases and 73.0 minutes in controls (P = .329). A subgroup of cases displayed clearly elevated CLTs. A CLT above the 90th or 95th percentile of controls was associated with an increased risk of BCS, with odds ratios of 2.4 (95% confidence interval, 1.1-5.5) and 3.4 (95% confidence interval, 1.2-9.7), respectively. In controls, only PAI-1 activity was significantly associated with CLT. Analysis of single nucleotide polymorphisms of fibrinolysis proteins revealed no significant differences between cases and controls. This case-control study provides the first evidence that an impaired fibrinolytic potential, at least partially caused by elevated PAI-1 levels, is related to the presence of BCS.
Article
The coagulation process is activated by tight control mechanisms, in which platelets play prominent and unique roles. In thrombosis and hemostasis, activated platelets regulate the coagulation system in various ways: by exposing a phosphatidylserine surface for thrombin formation, by supporting fibrin formation, and by regulating the retraction of a fibrin clot. In this review we discuss the involvement of platelet receptors, other membrane proteins, downstream signaling proteins, cytoskeleton-linked proteins and plasma proteins in these procoagulant functions. Studies with both genetically modified mice and pharmacological inhibitors indicate that, for collagen-adhered platelets, in part common signaling pathways lead to phosphatidylserine exposure, generation of thrombin and fibrin, and retraction of the fibrin clot. However, prolonged Ca(2+) elevation leads to thrombin generation, whereas integrin-dependent signaling stimulates fibrin clot retraction. Contact-dependent signaling pathways, triggered by homotypic platelet-platelet interactions, act in particular via the integrin route. © 2014 Elsevier Ltd. All rights reserved.
Article
This article presents thromboelastography (TEG) as an important assay to incorporate into anesthesia practice for development of evidence-based therapy of trauma patients receiving blood transfusions. The leading cause of death worldwide results from trauma. Hemorrhage is responsible for 30% to 40% of trauma mortality and accounts for almost 50% of the deaths occurring in the initial 24 hours following the traumatic incident. On admission, 25% to 35% of trauma patients present with coagulopathy, which is associated with a sevenfold increase in morbidity and mortality. The literature supports that routine plasma-based routine coagulation tests, such as prothrombin time, activated partial thromboplastin time, and international normalized ratio, are inadequate for monitoring coagulopathy and guided transfusion therapy in trauma patients. A potential solution is incorporating the use of the TEG assay into the care of trauma patients to render evidence-based therapy for patients requiring massive blood transfusions. Analysis with TEG provides a complete picture of hemostasis, which is far superior to isolated, static conventional tests. The result is a fast, well-designed, and precise diagnosis enabling more cost-effective treatment, improved clinical outcome, accurate use of blood products, and pharmaceutical therapies at the point of care.
Article
Background and objectives: It has been known for a long time that cirrhosis is associated with hyperfibrinolysis, which might contribute to an increased risk and severity of bleeding. However, recent papers have questioned the presence of a hyperfibrinolytic state in cirrhotic patients and postulated a rebalanced system owing to concomitant changes in both pro- and anti-fibrinolytic factors. Therefore we re-investigated the fibrinolytic state of cirrhotic patients using two different overall tests including a recently developed test for global fibrinolytic capacity (GFC) using whole blood. Patients and methods: Blood was collected from 30 healthy controls and 75 patients with cirrhosis of varying severity (34 Child-Pugh A, 28 Child-Pugh B and 13 Child-Pugh C). The plasma clot lysis time (CLT), which is inversely correlated with fibrinolysis, was determined as well as the GFC. Results: The mean CLT was 74.5 min in the controls and decreased significantly to 66.9 min in Child-Pugh class A patients, 59.3 min in class B patients and 61.0 min in class C patients, and hyperfibrinolysis existed in 40% of the patients. The median GFC was 1.7 μg mL(-1) in the controls and increased significantly to 4.0 μg mL(-1) in Child-Pugh class A patients, 11.1 μg mL(-1) in class B patients and 22.5 μg mL(-1) in class C patients, and hyperfibrinolysis existed in 43% of the patients. Taken together, 60% of the patients showed hyperfibrinolysis in at least one of the two global assays. Conclusion: A rebalanced fibrinolytic system may occur, but hyperfibrinolysis is found in the majority of patients with cirrhosis.
Article
Blood coagulation factor XIII (FXIII) is a tetrameric protein consisting of two catalytic A (FXIII-A) and two carrier/inhibitory B (FXIII-B) subunits. It is a zymogen, which becomes transformed into an active transglutaminase (FXIIIa) in the final phase of coagulation cascade by thrombin and Ca(2+). FXIII is essential for hemostasis, its deficiency results in severe bleeding diathesis. FXIIIa mechanically stabilizes fibrin by cross-linking its α-, and γ-chains. It also protects newly formed fibrin from fibrinolysis, primarily by cross-linking α(2)-plasmin inhibitor to fibrin. Beside the above prothrombotic effects, it is involved in limiting thrombus growth by down-regulating platelet adhesion to fibrin. Elevated FXIII level seems to be a gender-specific risk factor of both coronary artery disease and peripheral arterial disease, it represents an increased risk only in females. The association of FXIII level with the risk of ischemic stroke and venous thromboembolism was investigated only in a few studies from which no clear conclusion could be drawn. Among the FXIII subunit polymorphisms, concerning their effect on the risk of thrombotic diseases, only FXIII-A p.Val34Leu was investigated extensively. Meta-analyses of reported data suggest that this polymorphism provides a moderate protection against coronary artery disease and venous thromboembolism, but not against ischemic stroke. Gene-gene and gene-environmental interactions might modify its effect. Further studies are required to explore the effect of other FXIII subunit polymorphism on the risk of thrombotic diseases.
Article
Patients with von Willebrand disease (VWD), the most common inherited bleeding disorder, display large variation in bleeding tendency, which is not completely related to VWF levels. The cause of variability in clinical expression is largely unknown. The effect of plasma fibrinolytic capacity on bleeding tendency in VWD patients has not been investigated. We hypothesized that enhanced fibrinolysis may result in a more severe bleeding phenotype. Therefore, we measured the fibrinolytic potential in patients with moderate or severe VWD to investigate the contribution of fibrinolysis to the bleeding tendency. Fibrinolytic potential was measured as plasma clot lysis time (CLT) with and without addition of potato carboxypeptidase inhibitor (PCI) in 638 patients with moderate or severe VWD who participated in a nationwide multicentre cross-sectional study. Bleeding severity was measured using the Bleeding Score (BS).The CLTs were significantly longer, indicative of hypofibrinolysis, in men compared to women with VWD [106.2 (IQR 95.7-118.1) vs. 101.9 (IQR 92.8-114.0) min]. The CLTs prolonged with increasing age. No association was found between VWF or FVIII levels and CLT, or between VWF or FVIII levels and CLT(+PCI) . No association was observed for BS in a model with 10log-transformed CLT, adjusted for age, gender, VWF:Act and FVIII [b = 6.5 (95%CI -0.3 to 13.4)]. Our study showed that the plasma fibrinolytic potential does not influence bleeding tendency in VWD patients and therefore does not explain the variability in bleeding phenotype in VWD.
Article
The hemostatic process is a host defense mechanism to preserve the integrity of the closed high pressure circulatory system. This process must remain inactive but poised to minimize extravasation of blood from the vasculature following tissue injury. Given the complexity of the hemostatic mechanism, paradigms developed from biochemical and cell biological approaches have been revisited by studying thrombus formation in a live animal by intravital microscopy. Many of these paradigms have proven accurate, but others need to be reconsidered given the results of whole animal experiments.
Article
Severe sepsis induces coagulopathy, which may lead to disseminated intravascular coagulation (DIC). Thromboelastometry is a point-of-care whole blood coagulation monitor, which has been validated in human endotoxemia model. We assessed thromboelastometry in severe sepsis and overt DIC and investigated its applicability in differentiating sepsis-related coagulation disturbances. Thromboelastometry (EXTEM and FIBTEM tests) and traditional coagulation assays were analyzed in 28 patients with severe sepsis, 12 of who fulfilled the criteria of overt DIC on admission. Ten healthy persons served as controls. Coagulation parameters, clotting time, clot formation time (CFT), alpha angle, maximal clot firmness (MCF) and lysis index at 60 min, were registered. In patients with overt DIC, EXTEM MCF, CFT and alpha angle differed from that in both healthy controls and patients without DIC, indicating hypocoagulation (MCF 52, 63 and 68 mm; CFT 184, 88 and 73 s; and alpha angle 58, 72 and 76 degrees , respectively, P < 0.01 for all). In patients without DIC, the trend was toward hypercoagulation in EXTEM and FIBTEM MCF (68 vs. 63 mm, P = 0.042 and 23 vs. 15 mm, P = 0.034, respectively). Receiver operating characteristic curves showed that MCF, CFT and alpha angle discriminated patients with overt DIC moderately (area under curve 0.891, 0.815 and 0.828, respectively, P < 0.001 for all). Traditional coagulation assays showed progressively worsening coagulopathy from controls to septic patients without DIC and further to those with overt DIC. We conclude that thromboelastometry may be a valuable tool in assessing whole blood coagulation capacity in patients with severe sepsis with and without overt DIC.